Download A Breakthrough in Cancer: Therapy Monitoring

A Breakthrough in Cancer:
Therapy Monitoring
Therapy Selection
Personalized Medicine
Tony Ward, President – Rare Cell Division
Mike Grisham, CEO GPB
Value Proposition:
Addressing a key unmet medical need
• Goal: Eliminate unnecessary invasive tissue biopsy and
improve cancer patient outcomes
• How: Use simple blood test or “liquid biopsy” to enrich
circulating tumor and other rare cells
• Result: provide deep insights for selecting personalized
medical treatments resulting in better outcomes
• How we will win:
Our approach is the best path to presenting the researcher,
drug company and clinician with healthy individual rare tumor
cells ready for analysis and culture
• The US Liquid Biopsy Market alone is estimated to be $28.6Bn
GPB Scientific LLC Confidential
Core Technology: Gentle, uniform processing
of cells with virtually no cell loss
Array
direction
Average
flow
direction
• Allows separation of cells by
size using patented micropost
technology
• Will replace current bulk
processing approaches
Small
cell
Large
cell
• Micro-post separation has been
validated as superior to other
approaches
– Quality, Yield, and Purity
GPB Scientific LLC Confidential
Our Solution
• Delivers an easy to use
robust approach to
deliver cancer cells
that are:
– Inclusive of all
candidate cells
– Not damaged by
processing
– As close as possible to a
native state
– Ready for automated
clinical processes
GPB Scientific LLC Confidential
• Molecular analysis:
• Whole Genome
Amplification,
sequencing, Tumor
heterogeneity
• Functional tests:
• Actual drug response,
proliferation cycle etc.
• Imaging
• Enumeration, FISH,
Phenotyping
GPB’s Team Has A Proven Track Record
Management
Key Advisors
•
•
Mike Grisham MBA Founder/CEO
– Director of Center for Stem Cell
& Regenerative Medicine, U.
Maryland
– Member NCI Clinical Trials
– CEO and co-founder of Artemis
Health, Cellective Dx, Paradigm
Health
•
Lee Aurich MSM, CFO
– CFO Cellpoint Diagnostics, VP
roles at Aetna, Kaiser Permanente
– Director of planning 1984 LA
Olympics
•
•
Diether Recktenwald Ph.D.
– VP & Sr lead scientist roles at
Becton Dickinson, Amcell
(Miltenyi)
– Expert in cytometry and immunomagnetic cell separation
Tony Ward MBA, President Rare
Cells Division
– 28 year life science tools and
Diagnostics experience at Becton
Dickinson, eBioscience (VP),
Affymetrix (SVP/GM)
•
Curt Civin MD. (Chair)
•
Jim Sturm, Ph.D. Princeton
University
– Developer of Core technology
Khushroo Gandhi PhD, VP
Development & Manufacturing
– Site lead, Head of Mfg, Caliper Life
Sciences, R&D Director, Pilkington
Barnes Hind
GPB Scientific LLC Confidential
Financing plan
Sources
•
Materials and testing to
confirm approach. VOC &
chip iterations
•
Prototype & performance
molds, dispense system,
chemistry, Pilot Mfg
•
Production Mfg & initial
commercial team build
out, production molds
• Convertible Note $2M
• Series B – $6-8M
Milestone
Uses
GPB Scientific LLC Confidential
•
•
Getting the right cells
Superior performance
•
Functionally complete
alpha unit performing to
expectations
•
Commercial launch
Summary
• The personalized medicine market for cancer is big,
ready and the impact on healthcare will be
significant
• Base technology is validated, scalable and IP
protected
• Primary risk is execution
• The GPB team has done this before
GPB Scientific LLC Confidential